Healthcare ❯Pharmaceuticals ❯Drug Development
Sales Performance Eli Lilly
Despite beating Q1 earnings expectations, Merck adjusted its annual EPS guidance downward due to $200 million in tariff costs and a one-time charge tied to a licensing deal.